Polfa Grodzisk today Polfa Grodzisk has been functioning within the structure of European pharmaceutical concern Gedeon Richter Group since 2002. Set up in 1885, the chemical Company gained the recognition of medical circles and patients’ trust within over 120 years.

The prime objective of Polfa Grodzisk is supplying the public with the highest quality drugs, highly effective from a therapeutic standpoint, and at the same time – affordable.

Polfa Grodzisk is a manufacturer of generic drugs. These are reproduced drugs, which are less expensive biological equivalents of the “original” drugs. The Company specializes in manufacturing several therapeutic groups of medicines. Among the most important ones there are cardiological, dermatological and immunity-stimulating drugs. The fine quality of Polfa Grodzisk pharmaceutical agents has been quite often recognized, both by experts and patients. Within the last few years, the products from Grodzisk have been numerously receiving the “Golden Otis” award from consumers of the Polish pharmaceutical market. Our products are also available at foreign markets. The historical conditioning has been supporting export development to our Eastern neighbours. However, due to the marketing network of Gedeon Richter Group the products of Polfa are present at other European markets.

Dynamic development of the Company could have taken place due to long-standing, great investment expenditures intended for the factory infrastructure. The Company has at its disposal modern research, manufacturing and warehouse departments. Thus, it was possible to meet the new requirements Polish pharmaceutical companies faced  having joined the European Union. Engagement and expertise of our employees let us successfully finish adapting processes to new Union directives. The market is under constant changes and transformations. Having this in mind, we are convinced that the key to success lies in people, our most important capital. The employees of Polfa Grodzisk are its success creators. Within years, our highly qualified specialists became authors of 847 invention projects and 39 technological patents as well as winners of 12 awards and distinctions given for quality and innovativeness of products.